Reviewer’s report

Title: Nivolumab Induced Remitting Seronegative Symmetrical Synovitis with Pitting Edema in a Patient with Melanoma: A Case Report

Version: 0 Date: 07 Jan 2018

Reviewer: El Bairi Khalid

Reviewer’s report:


Please check/correct (comment if you disagree).

2- Background section: you references are in a disorder! we don't start by [24-35]! Please check/correct.

In addition, first paragraphs need to be referenced correctly. Please add recent references to this section.

3-The authors didn't mention anything in their manuscript about the dose/schedule of Nivolumab used to manage their melanoma patient!

4-The authors mentioned that their patient was treated with chemotherapy! Which chemotherapy? you didn't mention anything about this in the text. If you meant "nivolumab and ipilimumab" then please correct because these drugs don't belong to the chemotherapy. Please use oncology terms carefully.

5-Is there a place for Infliximab in the management of this rare toxicity ? Please check the updated NCCN guidelines for metastatic melanoma and provide detailed comments.

6-Some data in the case presentation section are not needed to be added to the manuscript as they will not add some additional support to the case presentation. Please add only data that can add some value to the diagnosis of this case report.

7-Please add the PET/CT of the lobe lung nodules as a supplementary figure.

8-Why didn't you use the MRI to characterize more the synovitis?

9-The surveillance imaging showing a complete resolution of metastatic disease during treatment with prednisone and nivolumab is absent! Please add it to the manuscript.
10-Some of your cited references are very old (except historical important notes), please update them.

11-Many abbreviations that you used in the text were not found in the list of abbreviations. Please add all of them.

Please add all changes in another color for the next revision.

**Level of interest**
Please indicate how interesting you found the manuscript:

An exceptional article

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal